Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
December 9, 2025
December 9, 2025
Medincell Awarded New Grant to Fight Malaria
November 24, 2025
November 24, 2025
UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025
November 5, 2025
November 5, 2025
New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
September 22, 2025
September 22, 2025
Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
September 17, 2025
September 17, 2025
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
July 30, 2025
July 30, 2025
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
